You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 10,774,085

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,774,085 protect, and when does it expire?

Patent 10,774,085 protects VITRAKVI and is included in two NDAs.

This patent has one hundred and eleven patent family members in thirty-eight countries.

Summary for Patent: 10,774,085

Title:	Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Abstract:	Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
Inventor(s):	Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Stamford, CT)
Assignee:	ARRAY BIOPHARMA INC. (Boulder, CO)
Application Number:	16/044,653
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 10,774,085

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION	⤷ Sign Up
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION	⤷ Sign Up
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,774,085

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3106463	⤷ Sign Up	301033	Netherlands	⤷ Sign Up
European Patent Office	3106463	⤷ Sign Up	PA2020504	Lithuania	⤷ Sign Up
European Patent Office	3106463	⤷ Sign Up	CA 2020 00013	Denmark	⤷ Sign Up
European Patent Office	3106463	⤷ Sign Up	122020000012	Germany	⤷ Sign Up
European Patent Office	3106463	⤷ Sign Up	LUC00150	Luxembourg	⤷ Sign Up
European Patent Office	3106463	⤷ Sign Up	2020C/507	Belgium	⤷ Sign Up
European Patent Office	3106463	⤷ Sign Up	CR 2020 00013	Denmark	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.